Lisaftoclax
Chronic Myeloid Leukemia
M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
77 Active assets in the Chronic Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nilotinib Novartis Pharmaceuticals | Phase 4 | BBB |
Cyclophosphamide City of Hope Medical Center | Phase 3 | BBB |
METHOTREXATE M.D. Anderson Cancer Center | Phase 3 | BBB |
Romidepsin Center for International Blood and Marrow Transplant Research | Phase 2 | BBB |
Therapeutic Allogeneic Lymphocytes University of Chicago | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Lisaftoclax is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BBB
Indicative · Phase 3
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →